Nuvalent, Inc.
NASDAQ:NUVLBiotechnology
-$0.03 today
- Market cap
- $9.13B
- Beta
- 1.15
- P/E (TTM)
- -21.6
- EPS (TTM)
- -$5.72
Volume 0.00M
Average 1.91M
NUVL Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Nuvalent, Inc.NASDAQ: NUVL
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $9.8M rose 115.5% year over year, ahead of the -8.3% change in trailing-twelve-month financing cash flow. Sequentially, it fell 98.0% from the prior quarter. Over 3 fiscal years it compounded at +27.5% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +115.5% holds above the trailing-twelve-month pace of -8.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 515.34M USD
- Year-over-year change
- -9.4%
- 4-year CAGR
- +12.8%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 515.34M | -9.4% |
| FY2024 | 2024-12-31 | 568.88M | +68.9% |
| FY2023 | 2023-12-31 | 336.85M | +35.3% |
| FY2022 | 2022-12-31 | 248.92M | -21.8% |
| FY2021 | 2021-12-31 | 318.22M | — |
Financing Cash Flow vs competitors
How NUVL compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -8.3% is the 5th highest of 9, against a peer median of +51.2%.
- Over three fiscal years its annual growth of +27.5% compares with a peer median of +9.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.24B USD | +1293.8% | +0.5% | 1750.0% | |
| LTM Jun 2026 | $1.21B USD | -20.7% | -86.7% | — | |
| LTM Sep 2026 | $776.82M USD | +949.7% | +45.3% | 172.3% | |
| LTM Sep 2026 | $719.96M USD | +120.5% | +122.7% | 2860.1% | |
| FY2025 | €531.94M EUR | +1785.8% | +154.7% | — | |
| LTM Mar 2026 | $520.59M USD | -8.3% | +27.5% | — | |
| LTM Jun 2026 | $88.79M USD | -18.1% | -29.1% | 11.4% | |
| LTM Sep 2026 | $15.76M USD | -106.1% | +0.6% | 5.6% | |
| LTM Sep 2026 | $3.86M USD | -99.6% | +18.2% | 0.1% | |
| Peer median (excluding NUVL) | — | +51.2% | +9.4% | 91.9% | |
Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (46.34M) | (81.85M) | (126.22M) | (260.76M) | (425.38M) |
| Depreciation & Amortization | 215K | (373K) | 0 | 0 | 0 |
| Deferred Income Tax | (215K) | (5.74M) | 0 | 0 | 0 |
| Stock-Based Compensation | 3.55M | 10.33M | 25.56M | 60.58M | 86.5M |
| Change in Working Capital | 1.94M | 6.93M | 11.03M | 11.84M | 19.21M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.64M | 4.21M | 2.17M | (4.05M) | 24.6M |
| Other Working Capital | 300K | 2.72M | 8.86M | 15.89M | (5.39M) |
| Other Non-Cash Items | 846K | 5.74M | (10.11M) | 3.27M | 44.46M |
| Operating Cash Flow | (40M) | (64.97M) | (99.74M) | (185.06M) | (275.21M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (221.04M) | (212.92M) | (459.49M) | (1.02B) | (1.06B) |
| Sales of Investments | 1.02M | 202.25M | 315.96M | 451.45M | 933.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (220.03M) | (10.67M) | (143.53M) | (573.51M) | (124.08M) |
| Debt Repayment | 284K | 0 | 0 | 0 | 0 |
| Common Stock Issued | 177.27M | 248.63M | 324.3M | 569.99M | 515.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.98M) | 286K | 12.55M | (1.11M) | 0 |
| Financing Cash Flow | 318.22M | 248.92M | 336.85M | 568.88M | 515.34M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 58.19M | 173.28M | 93.58M | (189.7M) | 116.05M |
| Free Cash Flow | (40M) | (64.97M) | (99.74M) | (185.06M) | (275.21M) |
Nuvalent, Inc.
NASDAQ:NUVL
Intrinsic Alpha fair value
Locked
Current Price
$123.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.